Skip to search formSkip to main contentSkip to account menu

17-allylamino-17-demethoxygeldanamycin hydroquinone

Known as: 17-allylamino-17-demethoxygeldanamycin hydroquinone salt, Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-, RETASPIMYCIN 
A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits… 
National Institutes of Health

Related topics

Related topics

4 relations
HSP90 Heat-Shock ProteinsSignal Transduction Inhibitionretaspimycin hydrochloride

Broader (1)

tanespimycin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer.
e14539 Background: Heat shock protein 90 (Hsp90) is a protein chaperone that regulates the proper folding, stability, and… 
2014
2014
HSP90 Inhibition Enhances Antimitotic Drug-Induced Mitotic Arrest and Cell Death in Preclinical Models of Non-Small Cell Lung Cancer
HSP90 inhibitors are currently undergoing clinical evaluation in combination with antimitotic drugs in non-small cell lung cancer… 
2013
2013
IJPRBS 376
  • Bharat
  • 2013
  • Corpus ID: 212543702
Heat shock protein stabilizing of various oncogenic client proteins to their active conformations that makes it promising anti… 
2013
2013
Abstract 3433: Deciphering the mechanism of synergy between the Heat Shock Protein 90 inhibitor retaspimycin HCl and docetaxel in preclinical models of non-small cell lung cancer.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Heat Shock Protein 90 (Hsp90) has emerged as an… 
Review
2011
Review
2011
Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer.
590 Background: Retaspimycin hydrochloride (IPI-504) is a potent, intravenously-administered heat shock protein 90 (Hsp90… 
2011
2011
Abstract 2827: Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Heat shock protein 90 (Hsp90) plays a role in… 
2010
2010
28th Annual JPMorgan Healthcare Conference--Affymax and Infinity Pharmaceuticals.
The JP Morgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies… 
2010
2010
Gateways to clinical trials.
(-)-Epigallocatechin gallate, Abafungin, ACE-031, Adapalene/benzoyl peroxide, AE-37, Aflibercept, AGS-003, Albiglutide… 
Review
2009
Review
2009
A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by…
8073 Background: IPI-504 (retaspimycin hydrochloride) is a potent, water-soluble heat shock protein 90 (Hsp90) inhibitor. IPI-504… 
2009
2009
A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel.
3547 Background: IPI-504 is a water-soluble heat shock protein 90 (Hsp90) inhibitor. IPI-504 causes the degradation of a variety… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)